{"id":"NCT04577404","sponsor":"Mitsubishi Tanabe Pharma America Inc.","briefTitle":"Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)","officialTitle":"A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-29","primaryCompletion":"2023-08-09","completion":"2023-08-09","firstPosted":"2020-10-06","resultsPosted":"2024-08-28","lastUpdate":"2025-09-08"},"enrollment":124,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"interventions":[{"type":"DRUG","name":"MT-1186","otherNames":["Oral Edaravone"]}],"arms":[{"label":"MT-1186","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.","primaryOutcome":{"measure":"Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death","timeFrame":"up to 96 Weeks","effectByArm":[{"arm":"MT-1186","deltaMin":616,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States","Canada","France","Germany","Italy","Japan"]},"refs":{"pmids":["40485494"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":124},"commonTop":["Fall","Muscular weakness","Constipation","Dyspnoea","COVID-19"]}}